Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

Background Phosphorylated tau (p-tau) epitopes in cerebrospinal fluid (CSF) are accurate
biomarkers for a pathological and clinical diagnosis of Alzheimer's disease (AD) and are …

Introduction We sought to establish the relationships between standard postmortem
measures of AD neuropathology and antemortem [11 C] PIB–positron emission tomography …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most
common cause of dementia. Beta-amyloid (Aβ) deposition and neurofibrillary tangles (NFTs) …

Protein misfolding and aggregation are characteristic of a wide range of neurodegenerative
disorders, including Alzheimer and Parkinson diseases. A hallmark of these diseases is the …

Abstract Background The Centiloid scale was developed to standardise the results of beta-
amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD …

Alzheimer's Disease (AD), the leading cause of senile dementia, is a progressive
neurodegenerative disorder affecting millions of people worldwide and exerting tremendous …

The centiloid scale was recently proposed to provide a standard framework for the
quantification of β-amyloid PET images, so that amyloid burden can be expressed on a …

Introduction Quantitative in vivo measurement of brain amyloid burden is important for both
research and clinical purposes. However, the existence of multiple imaging tracers presents …